This Is MS Multiple Sclerosis Knowledge & Support Community

In multiple previously conducted clinical trials for the treatment of patients with MS, Tcelna has demonstrated one of the safest side effect profiles of any marketed or development-stage MS therapy, as well as encouraging efficacy signals indicating Opexa’s therapy may have the potential to be both safe and effective for the treatment of both SPMS and RRMS patients. In Phase I/II studies involving SPMS patients treated with Tcelna (n=36), 80 percent of the patients treated with Tcelna showed no evidence of disease progression at 24 months (a 50% improvement, with respect to patients showing evidence of disease progression, over historical controls). Following two years of treatment, a subset of these patients (n=10) reported no worsening of their physical or psychological condition. Additionally, in 21 years of cumulative follow up in the same SPMS patients treated with Tcelna, the annualized relapse rate for this same subset of patients was reduced significantly compared to baseline and only one patient experienced a relapse during this time.

http://finance.yahoo.com/news/opexa-ini ... 8A2czQtDMD

scorpions wrote:

In multiple previously conducted clinical trials for the treatment of patients with MS, Tcelna has demonstrated one of the safest side effect profiles of any marketed or development-stage MS therapy, as well as encouraging efficacy signals indicating Opexa’s therapy may have the potential to be both safe and effective for the treatment of both SPMS and RRMS patients. In Phase I/II studies involving SPMS patients treated with Tcelna (n=36), 80 percent of the patients treated with Tcelna showed no evidence of disease progression at 24 months (a 50% improvement, with respect to patients showing evidence of disease progression, over historical controls). Following two years of treatment, a subset of these patients (n=10) reported no worsening of their physical or psychological condition. Additionally, in 21 years of cumulative follow up in the same SPMS patients treated with Tcelna, the annualized relapse rate for this same subset of patients was reduced significantly compared to baseline and only one patient experienced a relapse during this time.

http://finance.yahoo.com/news/opexa-ini ... 8A2czQtDMD

For those wondering why we hadn't heard about it before (after the 21 years of research noted above!), it's Tovaxin with a new name. And there's a whole Tovaxin sub-forum here at ThisIsMS.

Finally, to reflect its work in optimizing the overall manufacturing process and clinical development strategy for the program, Opexa’s lead product candidate, formerly known as Tovaxin, has been rebranded as Tcelna.

Thanks for clarifying for everyone. Tovaxin(Tcelna) once again takes a step forward but one has to wonder how long before it takes its historical two steps back! Interesting though.

Yeah well another DMD drug with what ??? - maybe a maxiumum of 30% chance of having any positive effect.
I personally don't have much faith in Big Pharma as doing anything real for people with MS as I feel that their real interest is in making money for the "corporations" so finding a cure or an effective relief of symptoms is definitely not in the best of those greedy money making interests.

You know 30% reduction feels good when I used to have 4 relapses a year.....

Azaeleaprawn wrote:Yeah well another DMD drug with what ??? - maybe a maxiumum of 30% chance of having any positive effect.
I personally don't have much faith in Big Pharma as doing anything real for people with MS as I feel that their real interest is in making money for the "corporations" so finding a cure or an effective relief of symptoms is definitely not in the best of those greedy money making interests.

Its not a drug.

CureOrBust wrote:

Azaeleaprawn wrote:Yeah well another DMD drug with what ??? - maybe a maxiumum of 30% chance of having any positive effect.
I personally don't have much faith in Big Pharma as doing anything real for people with MS as I feel that their real interest is in making money for the "corporations" so finding a cure or an effective relief of symptoms is definitely not in the best of those greedy money making interests.

Its not a drug.

...and Opexa is just a small biotech company, not 'big pharma'.

no opinions here, i just browsed here and wondered if opexa is publicly traded. short answer, yes.

jimmylegs wrote:no opinions here, i just browsed here and wondered if opexa is publicly traded. short answer, yes.

Yes, Opexa Therapeutics has been publicly traded for years. The former name of their company was PharmaFrontiers. Their stock has not done well historically. On April 14, 2004 they had a 1:50 reverse split. This was followed by a 1:10 reverse split on June 19, 2006.

Here is a short statement on the company's history from Wikipedia...

Founded in 2003, the company was originally known as PharmaFrontiers Corp. In October 2004 PharmaFrontiers acquired the privately held company Opexa Pharmaceuticals Inc. In June 2006 the company changed its name to Opexa Therapeutics, Inc.

In 2009 the company sold its stem cell technology to Novartis and focused all of its attention on the continuing development of Tovaxin.

NHE